Effect of enzymatically modified isoquercitrin in spontaneously hypertensive rats

Area of Science:

• Pharmacology
• Nutritional Science
• Cardiovascular Research

Background:

• Hypertension is a significant global health concern.
• Quercetin, a flavonoid, has shown potential health benefits.
• Enzymatically modified isoquercitrin (EMIQ) is a water-soluble derivative of quercetin.

Purpose of the Study:

• To investigate the antihypertensive effects of orally administered EMIQ in spontaneously hypertensive rats (SHR).
• To compare the efficacy of EMIQ with quercetin and a standard antihypertensive drug.

Main Methods:

• Administration of EMIQ (3 and 26 mg/kg/d) to spontaneously hypertensive rats (SHR).
• Monitoring of systolic blood pressure (SBP), mean blood pressure (MBP), and diastolic blood pressure (DBP).
• Comparison with equimolar quercetin and diltiazem (positive control).

Main Results:

• EMIQ significantly reduced SBP in SHR in a dose-dependent manner.
• EMIQ demonstrated a greater effect on SBP reduction compared to quercetin.
• No significant changes in MBP and DBP were observed in EMIQ groups, unlike the control group.

Conclusions:

• EMIQ possesses a dose-dependent antihypertensive effect in SHR, exceeding that of quercetin.
• The enhanced efficacy of EMIQ may be attributed to its improved bioavailability.
• EMIQ is a potential naturally-derived, safe food material with antihypertensive properties, possibly via improved endothelial nitric oxide production.